Download Citation
Article Source:
Cost-effectiveness of sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer in China
Kang S,
Yang S,
Jia Y,
Zhao S
(2026)
Cost-effectiveness of sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer in China.
PLOS ONE 21(3): e0343330.
https://doi.org/10.1371/journal.pone.0343330